

**TAIMOUR Y. LANGAEE**

2410 NW 95<sup>th</sup> street,  
Gainesville, FL 32606

(352)333-0260  
langaee@cop.ufl.edu

**EXPERIENCE:**

**Research Associate Professor;** 2002-Present  
**Director; UF Center for Pharmacogenomics (UFCPGx)**  
**Genotyping Core Laboratory,**  
**Dept. of Pharmacy Practice, College of Pharmacy,**  
**University of Florida**

- Directing the UFCPGx core genotyping laboratory
- Teaching Pharmacy professional and graduate students
- Advising pharmacy students
- Supervising and mentoring professional and graduate Pharmacy students and Postdoctoral fellows
- Supervising and training of laboratory Technicians
- Developing and establishing new assays
- Planning and establishing high throughput systems for genotyping
- Large scale genotyping, processing and genetic analysis of clinical samples
- Collaborating on clinical research projects in College of Pharmacy and other Colleges at UF and Other universities inside and outside of USA

**Postdoctoral Fellow;** 2001-2002  
**University of Florida,**  
**Dept. of Molecular Genetics and Microbiology**

- Plan, develop and execute projects
- Develop DNA chips for *Pseudomonas aeruginosa*
- Apply DNA chip technology to study gene duplication/deletion and expression profiles of CF (Cystic Fibrosis) isolates of *P. aeruginosa*
- Applying *in vivo* and *in vitro* conditions to study the expression profile of *P. aeruginosa* under CF lung environment
- Large scale screening of potential antimicrobial targets

**Postdoctoral Fellow;** 1999-2001  
**University of McGill and Montreal,**  
**Dept. of Molecular Genetics and Immunology**

- Involved in vaccine development project
- Establish new techniques
- Bioinformatics, search DNA and protein databases for sequence pattern, gene finding; prediction of protein sequence
- Provide training and supervision of graduate students and technicians
- Attend scientific meetings, interact and collaborate with other scientists

**Ph.D. Candidate;** 1994–1999  
**Laval University,**  
**Dept. of Molecular Genetics and Microbiology**

- Planing projects, designing appropriate experimental techniques, problem solving
- Gene discovery, using the existing search engines in NCBI to discover new genes involved in resistance to beta-lactam antibiotics in *Pseudomonas aeruginosa*

- Drug Resistance, elucidating the model for beta-lactam antibiotics resistance in Gram-negative bacteria and proposing new model for *Pseudomonas aeruginosa*,
- Analyzing and discussing results, attending scientific meetings, giving seminars
- Supervising technicians and students, teaching and assisting microbiology courses

**Director of Quality Control Laboratory  
Bayer Pharmaceutical Corporation**

1987–1994

- Write and Implement USP Microbiological procedures
- Review results and technical reports prior to release of products
- Evaluation of raw material, intermediates, and finished products
- Train personnel on cGMP, cGLP, SOP and other regulatory requirements.
- Supervise technicians, evaluate employee performance, and ensure career development

**EDUCATION:**

**Ph.D.**, Microbiology and Immunology  
Laval University, Ste-Foy, Quebec, Canada

1994-1999

**Master of Science (M.Sc.)**, Microbiology  
**Master of Science in Public Health (M.S.P.H.)**  
Tehran University of Medical Sciences, Tehran, Iran.

1984-1987

**Bachelor of Science (B.Sc.)**, Microbiology  
University of Texas at Arlington, Arlington, Texas, U.S.A.

1976-1979

**TEACHING:**

Drug Metabolism, Drug Transporters, and Pharmacogenomics; PHA 6936  
Therapeutic and Diagnostic Analysis and Pharmacogenomics; PHA 5113  
Clerkship Course PHA 5663 (Cardiovascular Research)  
Interdisciplinary Family Health (IFH);

**Committee Member:**

NIH Warfarin Study (COAG Trial) Genotyping Subcommittee, 2008-2009

NIH Warfarin Study (COAG Trial) Reference Laboratory Subcommittee, 2008-2009

**STUDENT ADVISING:**

Graduate student Advisor  
Faculty Advisor

**SUPERVISING AND MENTORING:**

Postdoctoral Fellows  
Professional/Undergraduate Research Mentoring  
UF Minority students

**GRANTS AND RESEARCH:**

**Co-Principal Investigator**

UF Research and Graduate opportunity Fund Grant (2003)

\$60,000

**Co-Principal Investigator**

UF Research and Graduate opportunity Fund Grant (2005)

\$92,500

**Co-Investigator**

U01 HL083459 (PI: Dr. Julie Johnson);  
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)  
08/2005-09/30/2010: \$11,149,034.  
D \$1,352,144; I \$262,835; T \$1,614,979

**Co-Investigator**

RO1-HL0747000; NIH/HLBI; (PI: Dr. Julie Johnson);  
10/01/2003-09/30/2008: D \$2,513,387; I \$1,004,312 ; T \$3,517,699.  
Hypertension Pharmacogenomics;

**Co-Principal Investigator**

Micromedic Technologies (R-283) \$70,000  
PI: Dr. Joseph Katz, College of Dentistry (Co-PI, 5%)

Project Title: Pharmacogenetics, pharmacokinetics and bone markers  
Award Date : 09/08/2008 thru 09/07/2010  
Pharmacogenomics study of Bisphosphonate-Associated Osteonecrosis of the Jaw (BONJ)

**Co-Investigator**

B 0435278 B AHA FL/Peurto Rico Affiliate (PI: Dr. Issam Zineh); (Co-investigator),  
07/2004 to 06/2007: \$80,000  
American Heart Association National Research Program  
Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

**Co-Investigator**

NIH (National Institute for Environmental Health Science, NIEHS); (PI: Dr. Peter Stacpoole);  
Health Effects of Chlorinated Compounds: Pharmacotoxicology of Trichloroethylene Metabolites 04/01/2005-  
03/30/2010: \$718,114; \$599,527 ; \$1,317,641

**Co-Investigator**

R21/R33 NIH Planning Grant (PI; Dr. Frank Catalanotto)  
10/01/2007 to 12/31/2010 \$50,000  
To plan and establish the feasibility of the key technology underlying a planned P50 proposal to support the  
expanding chemosensory clinical research program of the University of Florida's Center for Smell and Taste.

**Pending****Principal Investigator**

Investigator initiated research proposal to AstraZeneca Pharmaceutical Company,  
10/01/2007 to 11/30/2008 \$50,000.00  
Effect of *CYP3A5* polymorphisms on systemic exposure to Budesonide (Pulmicort Flexhaler)

**PUBLICATIONS:****Book Chapter:**

Langaee TY, and Shin J.(Book chapter) Concepts in Pharmacogenomics: The Genetic Basis of  
Pharmacogenomics American Society of Health-System Pharmacists(ASHP)2008 in press.

Langaee TY, and Zineh I.(Book chapter) Applied Molecular and Cellular biology In: Pharmacogenomics:  
Applications to Patient Care (Second edition). In preparation to be Published by American College of Clinical  
Pharmacy (ACCP).

Reviewed book chapter:

"Pharmacogenomics and Laboratory Tests", Basic Skills in Interpreting Laboratory Data edited by Mary Lee, 2008.

### Refereed Original Articles:

**International Warfarin Pharmacogenetics Consortium**, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med*. 2009 Feb 19;360(8):753-64.

Dungan JR, Conley YP, **Langaee TY**, Johnson JA, Kneipp SM, Hess PJ, Yucha CB. Altered Beta-2 Adrenergic Receptor Gene Expression in Human Clinical Hypertension. *Biol Res Nurs*. 2009 Mar 1. [Epub ahead of print]

Shin Jaekyu, Steven Kayser, **Taimour Langaee**. Pharmacogenetics: From Discovery to Patient Care.(In press in, *Am J Health Syst Pharm.*, 2009).

Anzeela M. Schentrup, John J. Lima, Hooman Allayee, Julie A. Johnson, and **Taimour Y. Langaee**. Genotyping the GGGCGG tandem repeat promoter polymorphism in the 5-lipoxygenase enzyme gene (*ALOX5*) by pyrosequencing assay. (In press in, *Genetic Testing and Molecular Biomarkers*, 2009).

Amber L. Beitelshes, Hrishikesh Navare, Danxin Wang, Yan Gong, Jennifer Wessel, James Moss, Taimour Y. Langaee, Rhonda M. Cooper-DeHoff, Wolfgang Sadee, Carl J. Pepine, Nicolas J. Schork, Julie A. Johnson. *CACNA1C* gene polymorphisms, cardiovascular disease outcomes and treatment response. *Circulation Cardiovascular Genetics*. (Accepted for publication, 2009).

Yuxin N. **Langaee TY**, Gong Y, Moss JI, Cooper-Dehoff RM, Pepine CJ, Johnson JA. DNA variations in Voltage-gated Calcium Channel Beta 2 Subunit (*CACNB2*) Gene and their association with adverse cardiovascular outcomes in the International Verapamil SR-trandolapril Study-GENetic Substudy (INVEST-GENES). (Submitted 2009).

Michael D. Caldwell, Tarif Awad, Julie A. Johnson, Brian F. Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, **Taimour Y. Langaee**, Charles Eby, Cristi King, Amy Brower, John R. Schmelzer, Ingrid Glurich, Humberto J. Vidaillet, Steven H Yale, Kai Qi Zhang, Richard L. Berg, and James K Burmester. CYP4F2 genetic variant alters required warfarin dose. *Blood*. 2008 Apr 15;111(8):4106-12. Epub 2008 Feb 4.

Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, **Langaee T**, Farnett LE, Voora D1, Veenstra DL, Glynn R, Barrett A, and McLeod HL. Use of Pharmacogenetics and Clinical Factors to Predict the Therapeutic Dose of Warfarin. *Clin Pharmacol Ther*. 2008 Feb 27; [Epub ahead of print]

Hassan M, York KM, Li H, Li Q, Gong Y, **Langaee TY**, Fillingim RB, Johnson JA, Sheps DS.  $\beta$ -Adrenergic Receptor Polymorphisms Predict Hemodynamic and Myocardial Ischemic Responses to Mental Stress in Patients with Coronary Artery Disease. *Arch Intern Med*. 2008 Apr 14;168(7):763-70.

Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, **Langaee TY**, Markowitz JS. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. *Am J Hum Genet*. 2008 Jun;82(6):1241-8. PMID: 18485328

Salha MD, Cheynier R, Halwani R, McGrath H, **Langaee TY**, Yassine Diab B, Fournier J, Parenteau M, Edgar J, Ko D, Sherring A, Bogdanovic D, Sekaly RP, Rud EW. Persistence of restricted CD4 T cell expansions in SIV-infected macaques resistant to SHIV89.6P superinfection. *Virology*. 2008 Aug 1;377(2):239-47

Gregory M. Cooper, Julie A. Johnson, **Taimour Y. Langaee**, Hua Fang, Ian B. Stanaway, Marylyn D. Ritchie, Dan M. Roden, Joshua D. Smith, Dave L. Veenstra, Allan E. Rettie, Mark J. Rieder. A whole-genome scan for large effect genes influencing warfarin dosing. *Blood*. 2008 Jun 5. [Epub ahead of print]

G. Oner Ozgon , **T.Y. Langaee** , H. Feng , N. Buyru , T. Ulutin , A.C. Hatemi , A. Siva , S. Saip , J.A. Johnson. *VKORC1* and *CYP2C9* polymorphisms are associated with warfarin dose requirements in Turkish patients. *Eur J Clin Pharmacol*. 2008 Jun 10. [Epub ahead of print]

Stacpoule PW, Kurtz TL, Han Z, **Langaee T**. Role of Dichloroacetate in the Treatment of Genetic Mitochondrial Diseases. *Adv Drug Deliv Rev*. 2008 Jul 4. [Epub ahead of print]

Gerhard T, Gong Y, Beitelshes AL, Lobmeyer M, Copper-DeHoff RM, **Langaee TY**, Schork NJ, Pepine CJ, Johnson JA. Association between Cardiovascular Outcomes, Diuretics Therapy and the  $\alpha$ -adducin Polymorphism: Results from the International Verapamil Study GENETic substudy (INVEST-GENES), *Am Heart J*. 2008 Aug;156(2):397-404. Epub 2008 Jun 20.

M.A. Pacanowski, Y. Gong, R.M. Cooper-DeHoff, N.J. Schork, M.D. Shriver, **T.Y. Langaee**, C.J. Pepine, J.A. Johnson, for the INVEST investigators.  $\beta$ -adrenergic receptor gene polymorphisms and  $\beta$ -blocker treatment outcomes in hypertension *Clin Pharmacol Ther*. 2008 Jul 9. [Epub ahead of print]

Pablo J. Pinedo, Claus D. Buergelt, G. Art Donovan, J. Elliot Williams, Pedro Melendez, Laurence Morel, Rongling Wu, **Taimour Y. Langaee** and D. Owen Rae. Association between *CARD15/NOD2* gene polymorphisms and paratuberculosis infection in Florida cattle. *Vet Microbiol*. 2008 Sep 19. [Epub ahead of print].

Johnson AD, Gong Y, Wang D, **Langaee TY**, Shin J, Cooper-DeHoff RM, Schork NJ, Binkley P, Pepine CJ, Johnson JA, Sadee W. Promoter polymorphisms in *ACE* (angiotensin-I converting enzyme) associated with clinical outcomes in hypertension. *Clin Pharmacol Ther*. 2008 Oct 22. [Epub ahead of print].

Mohamed-Eslam F.Mohamed, Reginald F. Frye, and **Taimour Y. Langaee**. Inter-population variation frequency of human inosine 5'-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms. *Genet Test*. 2008 Nov 2. [Epub ahead of print]

Mahsa Amoli, Parvin Amiri, Issam Zineh, **Taimour Y. Langaee**, Shirin Hasani Ranjbar *et al*. *CXCL5* gene polymorphism association with diabetes. *Mol Diagn Ther*. 2008;12(6):391-4.

Zineh I, Aquilante CL, **Langaee TY**, Beitelshes AL, Arant CB, Wessel TR, Schofield RS. *CXCL5* gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). *Cytokine* 2006 Mar 7;33(5):258-63. Epub 2006 Mar 29.

Aquilante CL, **Langaee TY**, Anderson PL, Zineh I, Fletcher CV. Multiplex PCR-pyrosequencing assay for genotyping *CYP3A5* polymorphisms. *Clin Chim Acta*. 2006 Oct;372(1-2):195-8. Epub 2006 May 15.

Ortega M, **Langaee TY**, Gong Y, Feng H, Johnson JA. G protein  $\beta 3$  subunit (GN $\beta 3$ ) Polymorphism and Hypertension. *UF Journal of Undergraduate Research*, Volume 7, Issue 4 - March/April 2006.

Aquilante CL, Zineh I, Beitelshes AL, **Langaee TY**. Common laboratory methods in pharmacogenomics studies. *Am J Health Syst Pharm*. 2006 Nov 1;63(21):2101-2110.

Shin J, Lobmeyer MT, Gong Y, Zineh I, **Langaee TY**, Yarandi H, Schofield RS, Aranda JM Jr, Hill JA, Pauly DF, Johnson JA. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. *Am J Cardiol* 2007 Jan 15;99(2):250-5.

**Langaee TY**, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of *CYP3A5* polymorphisms with hypertension and antihypertensive response to verapamil. *Clin Pharmacol Ther*. 2007 Mar;81(3):386-91.

Gong Y, Beitelshes AL, Wessel J, **Langaee TY**, Schork NJ, Johnson JA. Single nucleotide polymorphism discovery and haplotype analysis of  $Ca^{2+}$ -dependent  $K^{+}$  channel beta-1 subunit. *Pharmacogenetics and Genomics* 2007,17:267-275.

Lobmeyer MT, Gong Y, Terra SG, Beitelshes AL, **Langaee TY**, Pauly DF, Schofield RS, Hamilton KK, Patterson HJ, Adams KF Jr, Hill JA, Aranda JM Jr, Johnson JA. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. *Pharmacogenetics and Genomics* 2007 17:277-282.

Brunner M, Cooper-Dehoff RM, Gong Y, Karnes JH, **Langaee TY**, Pepine CJ, Johnson JA; INVEST Investigators. Factors Influencing Blood Pressure Response to Trandolapril Add-on Therapy in Patients taking Verapamil SR (From the INternational VErapamil SR/Tandolapril [INVEST] Study). *Am J Cardiol* 2007 Jun 1;99(11):1549-1554.

Levin, GM, Bowles TM, Ehrel MJ, **Langaee TY**, Tan JY, Johnson JA, and Millard W. Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness. *Mol Diagn Ther* 2007;11(3):155-160.

Beitelshes AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, **Langaee TY**, Shriver MD, Sadee W, Knot HJ, Pepine CJ, Johnson JA; for the INVEST Investigators. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). *Pharmacogenet Genomics* 2007 Sep;17(9):719-729.

Aquilante CL, **Langaee TY**, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. *Clin Pharmacol Ther*; 2006; 79:291-302.

Zineh I, Welder GJ, **Langaee TY**. Development and cross-validation of sequencing-based assays for genotyping common polymorphisms of the CXCL5 gene. *Clin Chim Acta*. 2006 Aug;370(1-2):72-5. Epub 2006 Mar 29.

Hruska MW, Amico JA, **Langaee TY**, Ferrell RE, Fitzgerald SM, Frye RF. The Effect of Trimethoprim on CYP2C8 Mediated Rosiglitazone Metabolism in Human Liver Microsomes and Healthy Subjects. *Br J Clin Pharmacol* (2005);59(1):70-79.

**Langaee TY** and Ronaghi M. Genetic Variation Analyses by Pyrosequencing. *Mutation Research* (2005);573(1-2):96-102.

Ronaghi M, **Langaee TY**. Single Nucleotide Polymorphism: Discovery, Detection and Analysis. *Personalized Medicine* (2005);2(2):111-125.

**Langaee TY**, and Zineh I. (Book chapter) Applied Molecular and Cellular biology In: *Pharmacogenomics: Applications to Patient Care*. Published by American College of Clinical Pharmacy (ACCP), August 2004.

Aquilante CL, Lobmeyer MT, **Langaee TY**, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. *Pharmacotherapy* 2004;24(6):720-6.

Johnson JA, **Langaee TY**, Zineh I and Beitelshes AL. Caution with  $\beta_1$ -adrenergic receptor genotyping. *Clinical Pharmacology & Therapeutics* 2004;76(2):185-86.

Hruska MW, Frye RF, **Langaee TY**. Pyrosequencing Method for Genotyping Cytochrome P450 CYP2C8 and CYP2C9 Enzymes. *Clin Chem*. 2004 Dec;50(12):2392-5.

**Langaee TY**., Dargis M and Huletsky A An ampD gene in *Pseudomonas aeruginosa* encodes a negative regulator of AmpC beta-lactamase expression. *Antimicrobial Agents and Chemotherapy* Dec. 1998;3296-3300.

**Langaee TY**., Gagnon, L and Huletsky, A. Inactivation of the ampD gene in *Pseudomonas aeruginosa* leads to moderate basal level and hyperinducible AmpC beta-lactamase expression. *Antimicrobial Agents and Chemotherapy* Mar. 2000:583-589.

## Membership

American Society for Clinical Pharmacology and Therapeutics (ASCPT)

**AWARDS:**

1996 ASM (American Society for Microbiology) Sustaining Member Student Grant.

1997 ASM (American Society for Microbiology) Sustaining Member Student Grant.

**ABSTRACTS AND PRESENTATIONS:**

I Zineh, PharmD, **TY Langaee, PhD**, JA Hill, MD, MS, DF Pauly, MD, PhD, RS Schofield, MD, JM Aranda, Jr., MD, and JA Johnson, PharmD. Type-A Natriuretic Peptide Receptor Polymorphism in Hypertension, Heart Failure Prognosis, and Response to Nesiritide. Presented as a poster at the 2002 American College of Clinical Pharmacy Meeting, Cardiology Practice and research Network, Albuquerque, NM, October 2002.

A. Albekairy, Pharm.D. , T. Luu, H. Yarandi, Ph.D., **T. Y. Langaee, Ph.D.**, C. Formea, Pham.D., V. Greene, PA., S. Fujita, MD., W. Vander Werf, MD., A. Hemming, MD, R. Howard, MD., A. Reed, MD., J. Karlix, Pharm.D., University of Florida, College of Pharmacy and medicine, Gainesville, FL. CYTOCHROME P-450 3A4\*1B AS PHARMACOGENOMIC PREDICTOR OF TACROLIMUS PHARMACOKINETICS AND CLINICAL OUTCOME IN THE LIVER TRANSPLANT RECIPIENTS. Presented as a poster at the 2002 American College of Clinical Pharmacy Meeting, Cardiology Practice and research Network, Albuquerque, NM, October 2002.

R.P. Rantinella, **T.Y. Langaee Ph.D.**, C. Aquilante PharmD., J.A. Johnson PharmD., University of Florida College of Pharmacy, Gainesville, FL. Association of Alpha 2b-Adrenergic Receptor Insertion/Deletion Polymorphism with Hypertension and Obesity. Selected for a poster presentation at the 104<sup>th</sup> Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Marriott Wardman Park Hotel, Washington, DC. April 2-5, 2003.

Aquilante CL, Yarandi HN, **Langaee TY**, Tromberg JS, Lopez LM, Waddell CD, Johnson JA. University of Florida, College of Pharmacy and medicine, Gainesville, FL. The Influence of Coagulation Factor and CYP2C9 Polymorphisms on Warfarin Dose. Abstract was accepted by American Heart Association and will be presented at the American Heart Association meeting, Orlando, Florida, November 9-12, 2003.

TM Bowles, PhrmD., GM Levin, PharmD., **TY Langaee, Ph.D.**, JY Tan, PharmD., HN Yarandi, Ph.D., JA Johnson, PharmD., WJ Millard, Ph.D. Assessment of serotonin type1A (5-HT1A) receptor genotype in a normal versus a depressed population and the relationship to predictability of antidepressant responsiveness. Abstract was accepted by American College of Clinical Pharmacy (ACCP) and will be presented at the 2003 American College of Clinical Pharmacy Meeting, Atlanta, GA, November 2-5, 2003.

Aquilante CL, Yarandi HN, **Langaee TY**, Tromberg JS, Lopez LM, Waddell CD, Johnson JA. The Influence of Coagulation Factor and CYP2C9 Polymorphisms on Warfarin Dose. University of Florida, College of Pharmacy and medicine, Gainesville, FL. Presented at the Annual Meeting of the American Heart Association (AHA) Meeting, Orlando, FL, November 2003.

**T. Y. Langaee, Ph.D.**, R. C. Givens, BS, A. Sloan, MS., P. B. Watkins, MD., J. A. Johnson, PharmD. ASSOCIATION OF CYP3A5\*3, \*6, AND \*7 POLYMORPHISMS WITH HYPERTENSION. University of Florida, Gainesville, FL, University of North Carolina, Chapel Hill, NC. Abstract was accepted by American Society for Clinical Pharmacology and Therapeutics (ASCPT) and presented at the 2004 American Society for Clinical Pharmacology and Therapeutics Meeting, Miami Beach, FL, March 25, 2004.

Gaston KL, Aquilante CL, **Langaee TY**, Lopez LM, Johnson JA. Vitamin K epoxide reductase polymorphisms rare in warfarin-treated population. Pharmacotherapy 2004; 24(10): 1458

J. R. Dungan, RN, MSN, ARNP, **T.Y. Langaee, MSPH, PhD**, J. A. Johnson, Pharm.D., and C. B. Yucha, PhD, RN. Exploring the Relationship Between Beta-2 Adrenergic Receptor Gene Polymorphisms and Biofeedback Outcomes in Hypertension. University of Florida, College of Pharmacy and medicine, Gainesville, FL. Abstract was accepted by Association for Applied Psychophysiology and Biofeedback (AABP) and will be presented at the 2004 Association for Applied Psychophysiology and Biofeedback Meeting, Colorado Springs, CO, April, 2004.

B.S. Belgado, L.H. Cavallari, **T. Langaee**, T. Okoro-chukwu J. A. Johnson, PharmD. ASSOCIATION OF  $\beta$ 2-Adrenergic Receptor Haplotype and Hypertension in African-Americans and Caucasians. University of Florida, Gainesville, FL, University of Illinois at Chicago, College of Pharmacy. Abstract was accepted by American Society for Clinical Pharmacology and Therapeutics (ASCPT) and presented at the 2004 American Society for Clinical Pharmacology and Therapeutics Meeting, Miami Beach, FL, March 25, 2004.

C. Formea, PharmD., T. Luu, BS, A. Albekairy, PharmD., H. Yarandi, Ph.D., **T. Langaee, Ph.D.**, V. Freene, PA., S. Fujita, MD., W. Van der Werf, MD., A. Hemming, MD., R. Howard, MD., Ph.D., A. Reed, MD., J. Karlix, PharmD. Cytochrome P-450 3A4, 3A5, and MDR-1 As Pharmacogenomic Predictors of Tacrolimus Pharmacokinetics And Clinical Outcomes in Liver Transplant recipients. University of Florida, Gainesville, FL. Abstract was accepted by American Society for Clinical Pharmacology and Therapeutics(ASCPT) and presented at the 2004 American Society for Clinical Pharmacology and Therapeutics Meeting, Miami Beach, FL, March 25, 2004.

Zineh I, Luo X, **Langaee TY**, Johnson JA, Chegini N. Th1- and Th2-related cytokine and chemokine balance in blood pressure responders and non-responders to metoprolol monotherapy. *Pharmacotherapy* 2004;24(10):1427.

Hruska MW, Cheong JA, Amico JA, **Langaee TY**, Frye RF. Effect of CYP2C8 Genotype on rosiglitazone pharmacokinetics. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 2005 and *Clin Pharmacol Ther* 2005; in press.

Hruska MW, Cheong JA, **Langaee TY**, Frye RF. Effect of St. John's Wort Administration on CYP2C8 Mediated Rosiglitazone Metabolism. Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 2005 and *Clin Pharmacol Ther* 2005; in press.

B.S. Belgado, L.H. Cavallari, **T. Langaee**, T. Okoro-chukwu J. A. Johnson, PharmD. ASSOCIATION OF  $\beta$ 2-Adrenergic Receptor Haplotype and Hypertension in African-Americans and Caucasians. *Clin Pharmacol Ther* 2004;75(2):P95.

C. Formea, PharmD., T. Luu, BS, A. Albekairy, PharmD., H. Yarandi, Ph.D., **T. Langaee, Ph.D.**, V. Freene, PA., S. Fujita, MD., W. Van der Werf, MD., A. Hemming, MD., R. Howard, MD., Ph.D., A. Reed, MD., J. Karlix, PharmD. Cytochrome P-450 3A4, 3A5, and MDR-1 As Pharmacogenomic Predictors of Tacrolimus Pharmacokinetics And Clinical Outcomes in Liver Transplant recipients. *Clin Pharmacol Ther* 2004;75(2):P39.

Zineh I, Luo X, **Langaee TY**, Johnson JA, Chegini N. Th1- and Th2-related cytokine and chemokine balance in blood pressure responders and non-responders to metoprolol monotherapy. *Pharmacotherapy* 2004;24(10):1427.

Hruska MW, Cheong JA, Amico JA, **Langaee TY**, Frye RF. Effect of CYP2C8 Genotype on rosiglitazone pharmacokinetics. *Clin Pharmacol Ther* 2005;77(2):P36.

Hruska MW, Cheong JA, **Langaee TY**, Frye RF. Effect of St. John's Wort Administration on CYP2C8 Mediated Rosiglitazone Metabolism. *Clin Pharmacol Ther* 2005;77(2):P35.

Hudson AA, Zineh I, Yarandi HN, **Langaee TY**, Pauly DF, Johnson JA. Angiotensin system polymorphisms and traditional risk factors as predictors of heart failure prognosis. *Clin Pharmacol Ther* 2005;77(2):P63.

Gong Y, Beitelshes AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, **Langaee TY**, Cooper-DeHoff RM, Pepine CJ, Johnson JA. BETA 2- ADRENERGIC RECEPTOR (B2AR) POLYMORPHISMS AND ANTIHYPERTENSIVE RESPONSE TO BETA-BLOCKER THERAPY IN THE INVEST TRIAL. *Clin Pharmacol Ther* 2005; 77 (2): P22.

Zineh I, **Langaee TY**, Welder GJ, Luo X, Arant CB, Wessel TR, Schofield RS, Chegini N. eNOS polymorphism is associated with early inflammation in normocholesterolemic patients. *Pharmacotherapy* 2005;25(3):473.

Zineh I, Arant CB, Wessel TR, **Langaee TY**, Welder GJ, Schofield RS. Apolipoprotein B/A ratio within the normal range is associated with elevated C-reactive protein in apparently healthy women. *Pharmacotherapy* 2005;25(3):453.

Hruska MW, Cheong JA, Amico JA, **Langaee TY**, Frye RF. Effect of CYP2C8 Genotype on rosiglitazone pharmacokinetics. *Clin Pharmacol Ther* 2005;77(2):P36.

Hruska MW, Cheong JA, **Langaee TY**, Frye RF. Effect of St. John's Wort Administration on CYP2C8 Mediated Rosiglitazone Metabolism. *Clin Pharmacol Ther* 2005;77(2):P35.

Hudson AA, Zineh I, Yarandi HN, **Langaee TY**, Pauly DF, Johnson JA. Angiotensin system polymorphisms and traditional risk factors as predictors of heart failure prognosis. *Clin Pharmacol Ther* 2005;77(2):P63.

Gong Y, Beitelshes AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, **Langaee TY**, Cooper-DeHoff RM, Pepine CJ, Johnson JA. BETA 2- ADRENERGIC RECEPTOR (B2AR) POLYMORPHISMS AND ANTIHYPERTENSIVE RESPONSE TO BETA-BLOCKER THERAPY IN THE INVEST TRIAL. *Clin Pharmacol Ther* 2005; 77 (2): P22.

**T.Y. Langaee**, H.N. Yarandi, D. Katz, R.M. Dehoff, J.M. Kehoe, A.S. Klocman, C.J. Pepine, J.A. Johnson. DIFFERENCES IN VERAPAMIL RESPONSE BETWEEN CYP3A5 GENOTYPES. *Clin Pharmacol Ther* 2006;79(2):P12.

I. Zineh, **T.Y. Langaee**, T.R. Wessel, C.B. Arant, R.S. Schofield. Influence of SLCO1B1 (OATP1B/OATP-C) gene polymorphisms on cholesterol responses to Atorvastatin. *Clin Pharmacol Ther* 2006;79(2):P5.

M. Bruner, J.H. Karnes, Y. Gong, **T.Y. Langaee**, R.M. Cooper-Dehoff, C.J. Pepine, J.A. Johnson. Association of Angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with blood pressure response to ACE inhibitor in a subgroup of patients of the International Verapamil SR/Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P14.

D.L. Kroetz, Z. Yu, **T.Y. Langaee**, J.A. Johnson. Functionally significant variants of CYP2J2 and EPHX2 are not associated with hypertension. *Clin Pharmacol Ther* 2006;79(2):P15.

Y. Gong, A.L. Beitelshes, L.A. Stauffer, **T.Y. Langaee**, R.M. Cooper-Dehoff, C.J. Pepine, J.A. Johnson. Beta Adrenergic Receptors polymorphisms are associated with response to beta-blocker therapy in the International Verapamil SR/Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P130.

J. Shin, M.T. Lobmeyer, Y. Gong, I. Zineh, **T.Y. Langaee**, H.N. Yarandi, D.F. Pauly, J.M. Aranda, R.S. Schofield, J.A. Hill, J.A. Johnson. A haplotype of Beta2- Adrenoceptor is associated with the increased risk for transplant or death in heart failure patients. *Clin Pharmacol Ther* 2006;79(2):P30.

J.A. Johnson, J.H. Karnes, M. Bruner, Y. Gong, **T.Y. Langaee**, R.M. Cooper-Dehoff, C.J. Pepine. Association of Lack of association of the Angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with cardiovascular and cerebrovascular outcomes in a subgroup of patients of the International Verapamil SR/Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P43.

I. Zineh, C.L. Aquilante, **T.Y. Langaee**, A. L. Beitelshes, T.R. Wessel, C.B. Arant, R.S. Schofield. Association of CXCL5 polymorphisms with plasma and leukocyte-produced epithelial neutrophil-activating peptide (ENA-78) concentrations. *Clin Pharmacol Ther* 2006;79(2):P59.

Pacanowski MA, Gong Y, **Langaee TY**, Cooper-DeHoff RM, Schork NJ, Pepine CJ, Johnson JA.  $\beta_2$ -adrenergic receptor polymorphisms and antihypertensive treatment outcomes in the International Verapamil SR/ trandolapril Study – GENETic Substudy (INVEST-GENES). [abstract] *Clin Pharmacol Ther* 2007;81(S1):S34. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 108<sup>th</sup> Annual Meeting, Anaheim, CA, March 2007.

**T.Y. Langaee**, B. Burkley, Y. Gong, I. Zineh. EFFECTS OF CYP3A4 AND CYP3A5 POLYMORPHISMS ON CHOLESTEROL RESPONSES TO ATORVASTATIN. [abstract] *Clin Pharmacol Ther* 2007;81(S1):S89.

Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 108<sup>th</sup> Annual Meeting, Anaheim, CA, March 2007.

Johnson AD, Gong Y, Wang D, **Langaee TY**, Shin J, Cooper-DeHoff RM, Schork NJ, Shriver MA, Binkley P, Pepine CJ, Johnson JA, Sadee W. Novel promoter polymorphisms in angiotensin-I converting enzyme (ACE) associated with clinical outcomes in hypertensive coronary artery disease (CAD) patients. Accepted for oral presentation at the American Society for Clinical Pharmacology and Therapeutics 109<sup>th</sup> Annual Meeting, Orlando, FL, March 2008.

H.A. Navare, A.L. Beitelshes, Pharm D, MPH, Y. Gong, PhD, **T.Y. Langaee, PhD**, R.M.Cooper-Dehoff, Pharm D, C.J.Pepine, MD, J.A.Johnson, Pharm D. CACNA1C POLYMORPHISMS AND CARDIOVASCULAR OUTCOMES IN THE INTERNATIONAL VERAPAMIL SR/TRANDOLAPRIL STUDY-GENETIC SUBSTUDY (INVEST-GENES). Accepted for poster presentation at the American Society for Clinical Pharmacology and Therapeutics 109<sup>th</sup> Annual Meeting, Orlando, FL, March 2008.

Mustafa Hassan, Kaki M. York, Haihong Li, Qin Li, Yan Gong, **Taimour Y. Langaee**, Roger B. Fillingim, Julie A. Johnson, David S. Sheps, University of Florida, Gainesville, FL.  $\beta$ 1-Adrenergic Receptor Polymorphism Predicts Mental Stress-induced Myocardial Ischemia in Patients with Coronary Artery Disease. Accepted at the American College of Cardiology 57th Annual Scientific Session, March 29-April 1, 2008, in Chicago, Illinois, USA.  
**Additionally, this abstract has been nominated as a finalist in the "Best Poster Award Competition" at ACC.08**

Shristi Rawal, Margaret R. Wallace, John E. Hayes, Linda M. Bartoshuk, Taimour Y. Langaee, Andrew Sholudko, Valerie B. Duffy. TAS1R1-intronic SNP Associations with Liking for Dietary Sources of Glutamate and for Orosensory Intensity. 2009.